Clinical data show increased levels of MMPs, especially MMP-9 and MMP-2, cathepsins, and neutrophil elastase in blood and tissue samples of the aneurysmal wall of AAA patients, while their antagonists are reduced [122,372,373]. This evidence concerns the gene MMP2 and triple-A syndrome.